Cnr1 Protein is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
| Property | Value | [1]
|----------|-------| [2]
| Protein Name | Cannabinoid Receptor 1 (CB1) | [3]
| Gene | CNR1 | [4]
| UniProt ID | P21554 | [5]
| PDB ID | 5TGZ, 6N4B | [6]
| Molecular Weight | 53 kDa (un-glycosylated) | [7]
| Subcellular Localization | Plasma membrane, intracellular vesicles |
| Protein Family | Class A G protein-coupled receptors (GPCR) |
The CB1 cannabinoid receptor is a typical Class A GPCR with:
| Drug | Type | Clinical Use |
|---|---|---|
| Dronabinol | Full agonist | Appetite stimulation, nausea |
| Nabilone | Synthetic agonist | Nausea, pain |
| Drug | Type | Clinical Use |
|---|---|---|
| Rimonabant | CB1 antagonist | Withdrawn (depression/suicide) |
The study of Cnr1 Protein has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
Di Marzo V. (2008). Endocannabinoid signaling in the brain. 2008. ↩︎
Piazza PV, et al. (2020). CNR1 and cannabis addiction. 2020. ↩︎
Fernández-Ruiz J, et al. (2000). Cannabinoid receptors in neurodegeneration. 2000. ↩︎
García-González D, et al. (2019). CB1 and Alzheimer's disease. 2019. ↩︎
Chiarlone A, et al. (2014). CB1 and Parkinson's disease. 2014. ↩︎
Hurd YL. (2017). Cannabis and the adolescent brain. 2017. ↩︎
Katona I, et al. (2015). Cannabinoid signaling in the brain. 2015. ↩︎